Literature DB >> 28334506

Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.

Floriane Gibault1, Fabrice Bailly1, Matthieu Corvaisier2, Mathilde Coevoet1, Guillemette Huet2, Patricia Melnyk1, Philippe Cotelle1.   

Abstract

Porphyrin derivatives, in particular verteporfin (VP), a photosensitizer initially designed for cancer therapy, have been identified as inhibitors of the YAP-TEAD interaction and transcriptional activity. Herein we report the efficient convergent synthesis of the dipyrrin half of protoporphyrin IX dimethyl ester (PPIX-DME), in which the sensitive vinyl group was created at the final stage by a dehydroiodination reaction. Two other dipyrrin derivatives were synthesized, including dipyrrin 19 [(Z)-2-((3,5-dimethyl-4-vinyl-2H-pyrrol-2-ylidene)methyl)-3,5-dimethyl-4-vinyl-1H-pyrrole], containing two vinyl groups. We found that VP and dipyrrin 19 showed significant inhibitory effects on TEAD transcriptional activity in MDA-MB-231 human breast cancer cells, whereas other compounds did not show significant changes. In addition, we observed a marked decrease in both YAP and TAZ levels following VP treatment, whereas dipyrrin 19 treatment primarily decreased the levels of YAP and receptor kinase AXL, a downstream target of YAP. Together, our data suggest that, due to their chemical structures, porphyrin- and dipyrrin-related derivatives can directly target YAP and/or TAZ proteins and inhibit TEAD transcriptional activity.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Hippo pathway; cancer; dipyrrins; non-photoinduced therapy; verteporfin

Mesh:

Substances:

Year:  2017        PMID: 28334506     DOI: 10.1002/cmdc.201700063

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  25 in total

1.  A Ca2+-ATPase Regulates E-cadherin Biogenesis and Epithelial-Mesenchymal Transition in Breast Cancer Cells.

Authors:  Donna K Dang; Monish Ram Makena; José P Llongueras; Hari Prasad; Myungjun Ko; Manuj Bandral; Rajini Rao
Journal:  Mol Cancer Res       Date:  2019-05-10       Impact factor: 5.852

2.  NTRK1 is a positive regulator of YAP oncogenic function.

Authors:  Xinyuan Yang; He Shen; Brian Buckley; Yanmin Chen; Nuo Yang; Ashley L Mussell; Mikhail Chernov; Lester Kobzik; Costa Frangou; Su-Xia Han; Jianmin Zhang
Journal:  Oncogene       Date:  2018-12-12       Impact factor: 9.867

3.  Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.

Authors:  Fanying Tang; Duo Xu; Shangqian Wang; Chen Khuan Wong; Alexander Martinez-Fundichely; Cindy J Lee; Sandra Cohen; Jane Park; Corinne E Hill; Kenneth Eng; Rohan Bareja; Teng Han; Eric Minwei Liu; Ann Palladino; Wei Di; Dong Gao; Wassim Abida; Shaham Beg; Loredana Puca; Maximiliano Meneses; Elisa de Stanchina; Michael F Berger; Anuradha Gopalan; Lukas E Dow; Juan Miguel Mosquera; Himisha Beltran; Cora N Sternberg; Ping Chi; Howard I Scher; Andrea Sboner; Yu Chen; Ekta Khurana
Journal:  Science       Date:  2022-05-27       Impact factor: 63.714

Review 4.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

5.  Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy.

Authors:  Masahiro Shibata; Akira Ooki; Yoshikuni Inokawa; Pritam Sadhukhan; M Talha Ugurlu; Evgeny Izumchenko; Enrico Munari; Giuseppe Bogina; Charles M Rudin; Edward Gabrielson; Anju Singh; Mohammad O Hoque
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

6.  Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface.

Authors:  Floriane Gibault; Mathilde Coevoet; Manon Sturbaut; Amaury Farce; Nicolas Renault; Frédéric Allemand; Jean-François Guichou; Anne-Sophie Drucbert; Catherine Foulon; Romain Magnez; Xavier Thuru; Matthieu Corvaisier; Guillemette Huet; Philippe Chavatte; Patricia Melnyk; Fabrice Bailly; Philippe Cotelle
Journal:  Cancers (Basel)       Date:  2018-05-08       Impact factor: 6.639

7.  SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.

Authors:  Qin He; Zhuoying Lin; Zhihui Wang; Wenjie Huang; Dean Tian; Mei Liu; Limin Xia
Journal:  Oncogene       Date:  2020-10-12       Impact factor: 9.867

Review 8.  YAP/TAZ Activation as a Target for Treating Metastatic Cancer.

Authors:  Janine S A Warren; Yuxuan Xiao; John M Lamar
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

9.  Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.

Authors:  Shumei Song; Yuan Li; Yan Xu; Lang Ma; Melissa Pool Pizzi; Jiankang Jin; Ailing W Scott; Longfei Huo; Ying Wang; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Namita D Shanbhag; Randy L Johnson; Jaffer A Ajani
Journal:  Mol Oncol       Date:  2020-04-07       Impact factor: 6.603

10.  YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.

Authors:  Krishanthan Vigneswaran; Nathaniel H Boyd; Se-Yeong Oh; Shoeb Lallani; Andrew Boucher; Stewart G Neill; Jeffrey J Olson; Renee D Read
Journal:  Clin Cancer Res       Date:  2020-11-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.